The FDA approved Guardant Health, Inc’s (NASDAQ: GH) Guardant360 CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU (elacestrant).